A Cutting-edge IP Litigation: the European Front of CRISPR Patent War


Type
Working Paper
Change log
Authors
Sanguanini, M 
Abstract

CRISPR/Cas9 is a gene editing technology that is revolutionising the way that scientists design biomedical research. In addition to this, CRISPR/Cas9 is opening promising avenues for applications in gene therapy, manufacturing, and agriculture. The commercial and disruptive potential of this invention is so promising that it sparked a ‘gold rush’ towards patenting CRISPR/Cas technologies. Two principal players weighed in to define the CRISPR/Cas9 patent landscape in the US: the University of California Berkeley (UCB) and the Broad Institute, a joint MIT-Harvard research institute. This ultimately led to a high-profile patent battle in front of the US Patent Trial and Appeal Board, where the Broad Institute prevailed in the first instance. The dispute, however, continues worldwide. In this Communication, I will focus on the European front of this litigation; the problem being not only who owns this technology in Europe, but also what are the potential impacts of patent conflicts between academic institutions on European policy and law.

Description
Keywords
Intellectual property, CRISPR/Cas9
Is Part Of